Abstract Number: 2684 • 2013 ACR/ARHP Annual Meeting
Impact Of Anti-Rheumatic Treatment On Immunogenicity Of Pandemic H1N1 Influenza Vaccine In Patients With Arthritis
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis Background/Purpose: An adjuvanted pandemic H1N1 influenza (pH1N1) vaccine (Pandemrix®) was…Abstract Number: 2685 • 2013 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies Are Associated With Radiographic Interstitial Lung Disease In Rheumatoid Arthritis, An Effect Potentiated By Smoking
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are implicated in the pathogenesis of interstitial lung disease (ILD) in rheumatoid arthritis (RA). Citrullinated proteins and the enzymes…Abstract Number: 2686 • 2013 ACR/ARHP Annual Meeting
Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab On Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the recommended first-line disease-modifying antirheumatic drug (DMARD) for the treatment of moderately to severely active rheumatoid arthritis (RA). Whether patients (pts)…Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…Abstract Number: 2688 • 2013 ACR/ARHP Annual Meeting
Methotrexate Dose Has Minimal Effects On Methotrexate-Related Toxicity In Patients With Early Rheumatoid Arthritis Treated In Combination With Adalimumab – Results Of Concerto Trial
Background/Purpose: Adalimumab is usually used in combination with 15-20 mg methotrexate (MTX) weekly in early rheumatoid arthritis (RA). Lower doses of MTX in combination with…Abstract Number: 2689 • 2013 ACR/ARHP Annual Meeting
Assessing Maintenance Of Remission After Withdrawal Of Etanercept Plus Methotrexate, Methotrexate Alone, Or Placebo In Early Rheumatoid Arthritis Patients Who Achieved Remission With Etanercept and Methotrexate: The Prize Study
Background/Purpose: In the PRIZE study patients (pts) with early (mean 6 mos. since symptom onset) moderate-severe rheumatoid arthritis (RA), who achieved remission after open-label treatment…Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting
Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry
Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…Abstract Number: 2692 • 2013 ACR/ARHP Annual Meeting
Evidence That Fat Metaplasia Is a Key Intermediary In The Development Of Sacroiliac Joint Ankylosis Following Repair Of Erosions In Patients With Spondyloarthritis
Background/Purpose: Fat metaplasia is detected as bright signal on T1W MRI and has been shown to develop after resolution of inflammation in spine and sacroiliac…Abstract Number: 2693 • 2013 ACR/ARHP Annual Meeting
Proof Of Concept: Enthesitis and New Bone Formation In Spondyloarthritis Are Driven By Mechanical Strain and Stromal Cells
Background/Purpose: Spondyloarthritides (SpA) are characterised by both peripheral and axial arthritis. Hallmarks of peripheral SpA are the development of enthesitis, most typically of the Achilles…Abstract Number: 2694 • 2013 ACR/ARHP Annual Meeting
HLA-B27 Expression Prevents Tnfα-Induced Inhibition Of Bone Formation in Vitro In IFNγ/Tnfα-Treated Osteoblasts
Background/Purpose: HLA-B27 predisposes to ankylosing spondylitis (AS), an immune-mediated inflammatory disease associated with osteitis, bone loss, and dysregulated bone formation, most notably in the axial…Abstract Number: 2655 • 2013 ACR/ARHP Annual Meeting
Therapeutic Effect Of β2GPI and Its Synthetic derivative Loaded Tolerogenic Dendritic Cells In Experimental Antiphospholipid Syndrome, Is Associated With miRNA 23b, 142-3p and 221 Expression and Tregs Upregulation
Background/Purpose: The importance of beta-glycoprotein I (beta2GPI)-specific CD4+ T cells in the development of pathogenic processes in patients with antiphospholipid syndrome (APS) and APS mice…Abstract Number: 2656 • 2013 ACR/ARHP Annual Meeting
Performance Of Prediction Models For Rheumatoid Arthritis Serologic Phenotypes Among Women Using Family History, Genetics and Environmental Factors
Background/Purpose: Family history (FH) of autoimmunity, genetics, and environmental factors have been associated with RA. The area under the receiver operating characteristic curve (AUC) can…Abstract Number: 2657 • 2013 ACR/ARHP Annual Meeting
Interactions Between Cigarette Smoking, Body Mass Index and Inflammatory Cytokine Levels In Determining The Risk Of Developing Rheumatoid Arthritis
Background/Purpose: Smoking and high body mass index (BMI) are risk factors for RA. Both are associated with increased systemic inflammation, with elevated C-reactive protein, interleukin…Abstract Number: 2658 • 2013 ACR/ARHP Annual Meeting
Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases
Background/Purpose: Dipeptidyl peptidase-4 inhibitors (DPP4i), such as linagliptin, saxagliptin, and sitagliptin, are oral glucose-lowering drugs for type 2 diabetes mellitus (T2DM). DPP4 is a transmembrane…
ACR Meeting Abstracts